Receptor-Mediated Redox Imbalance: An Emerging Clinical Avenue against Aggressive Cancers

Biomolecules. 2022 Dec 15;12(12):1880. doi: 10.3390/biom12121880.

Abstract

Cancer cells are more vulnerable to abnormal redox fluctuations due to their imbalanced antioxidant system, where cell surface receptors sense stress and trigger intracellular signal relay. As canonical targets of many targeted therapies, cell receptors sensitize the cells to specific drugs. On the other hand, cell target mutations are commonly associated with drug resistance. Thus, exploring effective therapeutics targeting diverse cell receptors may open new clinical avenues against aggressive cancers. This paper uses focused case studies to reveal the intrinsic relationship between the cell receptors of different categories and the primary cancer hallmarks that are associated with the responses to external or internal redox perturbations. Cold atmospheric plasma (CAP) is examined as a promising redox modulation medium and highly selective anti-cancer therapeutic modality featuring dynamically varying receptor targets and minimized drug resistance against aggressive cancers.

Keywords: aggressive cancer; cold atmospheric plasma; receptor; redox imbalance.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Oxidation-Reduction

Grants and funding

This work was supported by the National Natural Science Foundation of China (Grant No. 81972789), State Key Laboratory of Esophageal Cancer Prevention & Treatment (Grant No. K2022-005), and Fundamental Research Funds for the Central Universities (Grant No. JUSRP22011). The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.